H.C. Wainwright lowered the firm’s price target on Halozyme to $48 from $61 and keeps a Buy rating on the shares after the company detailed long-term guidance. Given the detailed parameters, along with updated Vyvgart expectations after two recent clinical setbacks, the firm decreased the price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
- Halozyme announces Roche receives EC marketing authorization of Tecentriq SC
- Halozyme to Host Investor Business Forum and Long-Term Outlook Call
- Halozyme price target lowered to $59 from $61 at Morgan Stanley
- Halozyme price target lowered to $45 from $46 at Goldman Sachs
